1. Functional Cellular Anti-Tumor Mechanisms are Augmented by Genetic Proteoglycan Targeting
- Author
-
Roland El Ghazal, So Young Kim, Scott C. Johns, Purva Gupta, Mark M. Fuster, and Elina I. Zuniga
- Subjects
0301 basic medicine ,CD4-Positive T-Lymphocytes ,Cancer Research ,T-Lymphocytes ,Ova, Ovalbumin ,CD8-Positive T-Lymphocytes ,Major Histocompatibility Complex ,chemistry.chemical_compound ,Carcinoma, Lewis Lung ,Mice ,0302 clinical medicine ,HS, Heparan sulfate ,Loss of Function Mutation ,Cytotoxic T cell ,HSPG, Heparan sulfate proteoglycan ,LysM, M Lysozyme locus ,LPS, Lipopolysaccharide ,Immunity, Cellular ,biology ,Chemistry ,Heparan sulfate ,Treg, Regulatory T cell ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,DC, Dendritic cell ,3. Good health ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Proteoglycans ,Sulfotransferases ,Original article ,T cell ,Clinical Sciences ,Antigen presentation ,TIL, Tumor Infiltrating Lymphocyte ,Major histocompatibility complex ,lcsh:RC254-282 ,TcR, T cell receptor ,03 medical and health sciences ,Sdc, Syndecan ,Immune system ,Lymphocytes, Tumor-Infiltrating ,Antigen ,Polysaccharides ,medicine ,CD11c, CD11c locus ,Animals ,Humans ,Oncology & Carcinogenesis ,MHC, Major histocompatibility complex ,Histocompatibility Antigens Class I ,BMDCs, Bone marrow dendritic cells ,Dendritic Cells ,Molecular biology ,CD11c Antigen ,030104 developmental biology ,Ndst, N-deacetylase/N-sulfotransferase ,biology.protein ,LLC, Lewis lung carcinoma ,SIINFEKL, Ova peptide sequence for Ova257 Ova264 ,Heparitin Sulfate ,CD8 - Abstract
While recent research points to the importance of glycans in cancer immunity, knowledge on functional mechanisms is lacking. In lung carcinoma among other tumors, anti-tumor immunity is suppressed; and while some recent therapies boost T-cell mediated immunity by targeting immune-checkpoint pathways, robust responses are uncommon. Augmenting tumor antigen-specific immune responses by endogenous dendritic cells (DCs) is appealing from a specificity standpoint, but challenging. Here, we show that restricting a heparan sulfate (HS) loss-of-function mutation in the HS sulfating enzyme Ndst1 to predominantly conventional DCs (Ndst1f/f CD11cCre+ mutation) results in marked inhibition of Lewis lung carcinoma growth along with increased tumor-associated CD8+ T cells. In mice deficient in a major DC HS proteoglycan (syndecan-4), splenic CD8+ T cells showed increased anti-tumor cytotoxic responses relative to controls. Studies examining Ndst1f/f CD11cCre + mutants revealed that mutation was associated with an increase in anti-tumor cytolysis using either splenic CD8+ T cells or tumor-infiltrating (TIL) CD8+ T cells purified ex-vivo, and tested in pooled effector-to-target cytolytic assays against tumor cells from respective animals. On glycan compositional analysis, HS purified from Ndst1f/f CD11cCre + mutant DCs had reduced overall sulfation, including reduced sulfation of a tri-sulfated disaccharide species that was intriguingly abundant on wildtype DC HS. Interestingly, antigen presentation in the context of major histocompatibility complex class-I (MHC-I) was enhanced in mutant DCs, with more striking effects in the setting of HS under-sulfation, pointing to a likely regulatory role by sulfated glycans at the antigen/MHC-I - T-cell interface; and possibly future opportunities to improve antigen-specific T cell responses by immunologic targeting of HS proteoglycans in cancer.
- Published
- 2020